NATIONAL
CANCER
INSTITUTE

NCI Cancer Bulletin
A Trusted Source for Cancer Research News
March 21, 2006 • Volume 3 / Number 12 E-Mail This Document  |  Download PDF  |  Bulletin Archive/Search  |  Subscribe


Bulletin Home

Featured Article
NCI Director von Eschenbach Nominated to Head FDA

Director's Update
Progress and Opportunity

Cancer Research Highlights
Gene Profiling Reveals Novel Subtype of Liver Cancer

Gene-Expression Signature Predictive in Node-Negative Breast Cancer

Folate in Food Cuts Pancreatic Cancer Risk

Lung Cancer Screening Trial Tests Silenced Genes as Biomarkers

Childhood Leukemia Incidence and Influenza in Great Britain

Funding Opportunities

NCI Funding Update

Featured Clinical Trial
Combination Therapy for Peritoneal Carcinomatosis

Meet NCI Experts at AACR

Notes
Science Writers' Seminar to Focus on Cancer Survivorship

DCEG Newsletter Wins Award

Measurement of Cancer Disparities Monograph Available

caBIG™ Annual Meeting Slated for April

TCGA Cancer Genome Pre-Application Meeting Scheduled

CCR Grand Rounds

Community Update
NIH Establishes Office to Manage and Fund Transdisplinary Research Initiatives

Bulletin Archive

Page Options
Print This Page
Print This Document
View Entire Document
E-Mail This Document
View/Print PDF
Featured Article

NCI Director von Eschenbach Nominated to Head FDA

Last week President Bush nominated current NCI Director Dr. Andrew C. von Eschenbach to be the next commissioner of the Food and Drug Administration (FDA). Dr. von Eschenbach has served as the interim FDA commissioner since late last September, after Dr. Lester Crawford resigned from the position.

"I am deeply honored to be nominated to head the FDA, and I look forward to continuing to serve our great nation in this capacity," Dr. von Eschenbach said. "As a result of this nomination, I intend to resign my position as NCI director.

"I cannot overstate how much I've enjoyed working at NCI," he said. "The staff at NCI, from the senior leadership on down, are among the most highly talented and dedicated group of people I've ever worked with. NCI is a very special organization, and I will miss my interactions with staff and the committed members of the research and advocacy communities very much."  Read more  

Director's Update

Progress and Opportunity

Dr. Andrew C. von Eschenbach Last week, President Bush nominated me to be the commissioner of the Food and Drug Administration (FDA). I have enjoyed serving as interim FDA commissioner, a post I have held since last September, and am honored by the President's decision to nominate me for this important public health leadership position.

I look forward to sharing with members of Congress and the medical community my aspirations for this critical agency, and how I believe we can take advantage of the numerous opportunities afforded by advances in science and technology to protect and improve our nation's health.  Read more  



The NCI Cancer Bulletin is produced by the National Cancer Institute (NCI). NCI, which was established in 1937, leads the national effort to eliminate the suffering and death due to cancer. Through basic, clinical, and population-based biomedical research and training, NCI conducts and supports research that will lead to a future in which we can identify the environmental and genetic causes of cancer, prevent cancer before it starts, identify cancers that do develop at the earliest stage, eliminate cancers through innovative treatment interventions, and biologically control those cancers that we cannot eliminate so they become manageable, chronic diseases.

For more information on cancer, call 1-800-4-CANCER or visit http://www.cancer.gov.

NCI Cancer Bulletin staff can be reached at ncicancerbulletin@mail.nih.gov.

Next Section >


A Service of the National Cancer Institute
Department of Health and Human Services National Institutes of Health USA.gov